(Press-News.org) PHILADELPHIA--Medications to treat high blood pressure did not affect outcomes among patients hospitalized with COVID-19, found an international team led by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, published today in The Lancet Respiratory Medicine, is the first randomized controlled trial to show there is no risk for patients continuing these medications while hospitalized for COVID-19.
As part of the REPLACE COVID trial, investigators examined whether ACE inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) -- two classes of medications to treat high blood pressure -- could help mitigate complications or lead to more severe symptoms. More than 49 million U.S. adults take medication to treat hypertension, and among those, about 83 percent (41 million) take an ACEI or ARB, according to the Centers for Disease Control and Prevention.
Early during the pandemic, a concern arose regarding the use of ACEIs or ARBs in the setting of COVID-19, since some studies had suggested that these medications could upregulate cellular receptors for the SARS-CoV-2 virus potentially aiding viral replication. However, it was also considered that some effects of these medications could be protective against the virus.
"Observational studies were rapidly done, but randomized trials are important to establish a definitive answer regarding the potential impact of these commonly used blood pressure medications in the setting of COVID-19," said study corresponding and senior author Julio A. Chirinos, MD, PhD, an associate professor of Cardiovascular Medicine in the Perelman School of Medicine. "Our trial results importantly show that these medications can be safely continued for patients hospitalized with COVID-19."
ACEIs and ARBs are among the most commonly prescribed medications in the world, and a potential link between those medications and COVID-19 outcomes has large global health implications, the authors say. Several observational studies suggested no association between outpatient ACEI or ARB use and risk of COVID-19 hospitalization, but high-quality randomized trial evidence was lacking, until now.
For the trial, investigators enrolled 152 participants across several countries between March 31 and August 20, 2020, who were hospitalized with COVID-19 and already using one of the medications. The participants were randomly assigned to either stop or continue taking their prescribed medication and closely monitored to evaluate the effect of temporarily stopping the therapy.
Investigators developed an innovative global rank score to classify patient outcomes based on four factors: time to death, length of time supported by mechanical ventilation or extracorporeal membrane oxygenation (ECMO), length of time on renal replacement therapy, and a modified sequential organ failure assessment score. Through analyzing the patient outcome data, the team found discontinuation of ACEIs and ARBs compared with continuation of these medications had no effect on the global rank score.
This evidence supports international society recommendations for continuing ACEI and ARB therapy in patients admitted to the hospital with COVID-19, unless there is a clear, alternate medical issue with ongoing therapy.
"At the start of the pandemic, patients were worried about perceived harm based on limited and incomplete information, and unfortunately, some insisted on stopping their medications. However, stopping these medications unnecessarily can increase the risk for severe complications, including heart attack and stroke," said first author Jordana B. Cohen, MD, MSCE, an assistant professor in the division of Renal-Electrolyte and Hypertension, and a co-principal investigator with Chirinos. "Now we have high quality evidence to support our recommendation that patients continue to take these medications as prescribed."
Currently, trials are underway to determine if use of these medications is effective for the treatment of COVID-19.
The trial was sponsored by the investigators from the various enrolment centers; the REPLACE COVID Trial Social Fundraising Campaign supported a portion of enrolment at Penn Medicine; FastGrants supported enrolment at the University of Michigan.
INFORMATION:
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.
Touted by makers as a "healthy" alternative to traditional nicotine cigarettes, new research indicates the chemicals found in e-cigarettes disrupt the gut barrier and trigger inflammation in the body, potentially leading to a variety of health concerns.
In the study, published Jan. 5, 2021 in the journal END ...
Abu Dhabi, UAE, January 6, 2021: To provide effective aid to children who live in areas of conflict it is necessary to understand precisely how they have been impacted by the crises around them. One area of importance is the effect of conflict and trauma on a child's development and education.
In a new paper, Global TIES for Children researchers J. Lawrence Aber, Carly Tubbs Dolan, Ha Yeon Kim, and Lindsay Brown, present a review of opportunities and challenges they have encountered in designing and conducting rigorous research that advances our understanding of this effect. Global TIES for Children, an international research center based at NYU Abu Dhabi and NYU New York, generates evidence to support the most effective humanitarian and development aid to promote children's ...
New research indicates adolescent offspring of the menacing sabre-toothed predator, Smilodon fatalis, were more momma's cubs than independent warriors.
A new study by scientists at the Royal Ontario Museum (ROM) and University of Toronto, published January 7, 2021 in iScience¸ documents a family group of the sabre-toothed cats whose remains were discovered in present-day Ecuador. By studying the fossils, collected for the ROM in the early 1960s, the scientists were able to show that while the supersized Ice Age cats grew quite quickly, they also appeared to stay with their mother for longer than some other large cats before forging their own path.
"This study started out as a simple description ...
Patients and healthcare providers at the Princess Margaret Cancer Centre rated virtual care during COVID-19 as highly satisfactory overall for quality of care and convenience, while at the same time saving patients millions in costs.
Research led by Princess Margaret Radiation Oncologist Dr. Alejandro Berlin showed that virtual care can be implemented rapidly and safely across a highly-specialized and high-volume cancer centre. Eighty (80) per cent of patients reported they were either very satisfied or satisfied with it, citing convenience as a main ...
Wearing cooling vests during a COVID-19 shift ensures that nurses experience less heat during their work. During their shifts, nurses wear protective clothing for three hours in a row, during which the temperature can rise to as much as 36 degrees. The cooling vests offer such effective cooling that they are now part of the standard work clothing for nurses in the COVID nursing departments at Radboud university medical center.
Due to the high level of contagiousness present with COVID-19, health care personnel have to work in protective clothing that is not ...
The "Executive Order on Promoting American Seafood Competitiveness and Economic Growth," issued by the Trump administration in May 2020, lays out a plan to expand the U.S. seafood industry, especially aquaculture, and enhance American seafood competitiveness in the global market.
The goals of the directive are focused largely on growth and expansion of the industry, which includes wild-caught fisheries and farm-raised products, as well as recreation, processing and other industries that rely on fishing.
"The seafood industry in general is worth about $200 billion and accounts for 2 million jobs in the United States," ...
Wuhan City in China was the first place to report COVID-19 in the world and--between December 2019 and May 2020--caused nearly two-thirds of all COVID-19 cases in China. Now, researchers reporting in PLOS Neglected Tropical Diseases have tested more than 60,000 healthy individuals in China for SARS-CoV-2 antibodies and concluded that thousands of Wuhan residents were infected with asymptomatic cases of COVID-19 after the infection was believed to be under control in China.
Rapid antibody tests are used to diagnosis present and past infections with the SARS-CoV-2 virus that causes COVID-19; positive IgG antibodies suggests a previous infection while IgM antibodies mean a current or recent ...
A new computational analysis suggests that a vaccine or medication that could shorten the infectious period of COVID-19 may potentially prevent millions of cases and save billions of dollars. The study was led by Bruce Lee along with colleagues in the Public Health Informatics, Computational, and Operations Research (PHICOR) team headquartered at the CUNY Graduate School of Public Health and Health Policy and the Lundquist Research Institute at Harbor-UCLA Medical Center, and publishes in the open-access journal PLOS Computational Biology.
While much of the ...
The fatal threat from diarrhoea and pneumonia to young children in the world's poorer countries can be drastically reduced by using traditional performing arts to encourage mothers to provide youngsters with safe food and water, a new study reveals.
The Gambia, like many other Low- and Middle-income Countries (LMICs) faces high rates of under-five deaths due to diarrhoea and pneumonia - the two highest causes of death in this age group in this country and globally.
Children transitioning from breastfeeding to eating food are at most risk, as complementary food becomes contaminated. Researchers working in The Gambia discovered that mothers' food safety and hygiene behaviours were massively improved by a low-cost behaviour change community ...
ANN ARBOR--A team of researchers has discovered an antibody that blocks the ability of the dengue virus to cause disease in mice. The findings open the potential for developing effective treatments and designing a vaccine for dengue and similar diseases.
Dengue virus, a member of a group of viruses called flaviviruses, causes 50 to 100 million cases of dengue disease each year, with no effective treatment or vaccine. Other members of this group include the viruses that cause Zika, yellow fever and West Nile fever.
In a new study scheduled to publish Jan. 8 in the journal Science, researchers from the University of California, Berkeley, and the University of Michigan revealed how an antibody called 2B7 neutralizes one specific protein made ...
